Rock Point Advisors LLC Has $248,000 Position in Eli Lilly and Company (NYSE:LLY)

Rock Point Advisors LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 10.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 280 shares of the company’s stock after selling 31 shares during the quarter. Rock Point Advisors LLC’s holdings in Eli Lilly and Company were worth $248,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Principal Street Partners LLC increased its stake in Eli Lilly and Company by 57.2% in the third quarter. Principal Street Partners LLC now owns 3,585 shares of the company’s stock valued at $3,233,000 after acquiring an additional 1,305 shares during the period. Brooklyn Investment Group grew its stake in shares of Eli Lilly and Company by 7.7% in the 3rd quarter. Brooklyn Investment Group now owns 5,639 shares of the company’s stock valued at $4,996,000 after purchasing an additional 404 shares during the period. Covington Investment Advisors Inc. raised its holdings in shares of Eli Lilly and Company by 0.5% in the 3rd quarter. Covington Investment Advisors Inc. now owns 20,629 shares of the company’s stock worth $18,276,000 after buying an additional 101 shares in the last quarter. Quantbot Technologies LP raised its holdings in shares of Eli Lilly and Company by 115.3% in the 3rd quarter. Quantbot Technologies LP now owns 3,757 shares of the company’s stock worth $3,328,000 after buying an additional 2,012 shares in the last quarter. Finally, D.A. Davidson & CO. lifted its position in shares of Eli Lilly and Company by 1.9% during the 3rd quarter. D.A. Davidson & CO. now owns 43,893 shares of the company’s stock worth $38,887,000 after buying an additional 839 shares during the period. 82.53% of the stock is owned by institutional investors.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Up 3.4 %

LLY traded up $25.81 during trading on Tuesday, reaching $780.81. The company had a trading volume of 1,526,977 shares, compared to its average volume of 3,193,379. The company has a market cap of $741.24 billion, a P/E ratio of 81.62, a PEG ratio of 2.83 and a beta of 0.43. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The business’s fifty day moving average price is $861.63 and its 200 day moving average price is $870.20.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the prior year, the firm posted $0.10 earnings per share. The company’s revenue was up 20.4% compared to the same quarter last year. Equities analysts anticipate that Eli Lilly and Company will post 13.2 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.67%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Analysts Set New Price Targets

A number of analysts have weighed in on LLY shares. Bank of America lowered their price target on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. BMO Capital Markets lifted their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Finally, Citigroup raised their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a report on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.